BioLineRx (NASDAQ:BLRX – Get Free Report) and Carisma Therapeutics (NASDAQ:CARM – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
Earnings & Valuation
This table compares BioLineRx and Carisma Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLineRx | $17.25 million | 0.88 | -$9.22 million | ($2.41) | -1.44 |
| Carisma Therapeutics | $10.77 million | 0.18 | -$60.48 million | ($0.80) | -0.06 |
Institutional & Insider Ownership
1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility & Risk
BioLineRx has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Carisma Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
Profitability
This table compares BioLineRx and Carisma Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLineRx | -45.34% | -49.74% | -17.54% |
| Carisma Therapeutics | -254.28% | N/A | -192.17% |
Analyst Ratings
This is a summary of current ratings and recommmendations for BioLineRx and Carisma Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLineRx | 1 | 0 | 1 | 1 | 2.67 |
| Carisma Therapeutics | 1 | 4 | 1 | 1 | 2.29 |
BioLineRx presently has a consensus price target of $26.00, suggesting a potential upside of 647.13%. Carisma Therapeutics has a consensus price target of $1.93, suggesting a potential upside of 4,140.09%. Given Carisma Therapeutics’ higher probable upside, analysts clearly believe Carisma Therapeutics is more favorable than BioLineRx.
Summary
Carisma Therapeutics beats BioLineRx on 7 of the 13 factors compared between the two stocks.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
About Carisma Therapeutics
Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
